1. Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression
- Author
-
Alexia Adams, Sanjay P Ahuja, Alfred P. Gillio, Roberta H. Adams, Lisa Eidenschink Brodersen, Sureyya Savasan, Mingwei Fei, Michael R. Loken, Michael A. Pulsipher, Kwang Woo Ahn, Morris Kletzel, David A. Jacobsohn, Pierre Teira, Barbara Bambach, Jeffrey H. Davis, David C. Delgado, Ann E. Haight, Reggie E. Duerst, Allen R. Chen, Mehmet Ozkaynak, Christopher C. Dvorak, Kimberly A. Kasow, Soheil Meshinchi, Troy C. Quigg, Madhu Gowda, Brent R. Logan, Julie-An Talano, Kirk R. Schultz, Victor Lewis, Bronwen E. Shaw, Michael Boyer, David Mitchell, David M. Loeb, Albert Kheradpour, Andrew C. Harris, Hilary Haines, Eneida R. Nemecek, Amy K. Keating, Shalini Shenoy, Robert J. Greiner, Aleksandra Petrovic, Marie Olszewski, Paul L. Martin, Terry J. Fry, Michelle Hudspeth, Alexandra Cheerva, Sana Khan, Monica Bhatia, and Steven P. Margossian
- Subjects
Myeloid ,Male ,Oncology ,Cytogenetics and molecular genetics ,Neoplasm, Residual ,Transplantation Conditioning ,medicine.medical_treatment ,Disease ,Hematopoietic stem cell transplantation ,Regenerative Medicine ,0302 clinical medicine ,Stem Cell Research - Nonembryonic - Human ,hemic and lymphatic diseases ,Gene expression ,Child ,Cancer ,Pediatric ,screening and diagnosis ,Leukemia ,medicine.diagnostic_test ,Stem cell transplantation ,Hematopoietic Stem Cell Transplantation ,Hematopoietic stem cell ,Myeloid leukemia ,Hematology ,Allografts ,Flow Cytometry ,Laboratory hematology ,Detection ,Leukemia, Myeloid, Acute ,medicine.anatomical_structure ,Residual ,Child, Preschool ,030220 oncology & carcinogenesis ,Female ,Unrelated Donors ,4.2 Evaluation of markers and technologies ,Homologous ,Adult ,Pediatric Research Initiative ,medicine.medical_specialty ,Measurable residual disease ,Adolescent ,Pediatric Cancer ,Clinical Sciences ,Immunology ,Acute ,Article ,Disease-Free Survival ,Flow cytometry ,03 medical and health sciences ,Rare Diseases ,Clinical Research ,Internal medicine ,Genetics ,medicine ,Humans ,Transplantation, Homologous ,Preschool ,WT1 Proteins ,Transplantation ,business.industry ,Inflammatory and immune system ,Infant, Newborn ,Infant ,Wilms' tumor ,Newborn ,Stem Cell Research ,medicine.disease ,Neoplasm ,business ,Cytometry ,030215 immunology - Abstract
We enrolled 150 patients in a prospective multi-center study of children with acute myeloid leukemia undergoing hematopoietic stem cell transplant (HSCT) comparing detection of measurable residual (MRD) disease by a “Difference from Normal” flow cytometry (ΔN) approach with assessment of Wilms tumor 1 (WT-1) gene expression without access to the diagnostic specimen. Prospective analysis of the specimens using this approach showed that 23% of patients being screened for HSCT had detectable residual disease by ΔN (0.04–53%). Of those patients who proceeded to transplant as being in morphologic remission, 10 had detectable disease (0.04–14%) by ΔN. The disease free survival of this group was 10% (0–35%), compared to 55% (46–64
- Published
- 2018